FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110032523> ?p ?o ?g. }

• W2110032523 endingPage "8" @default.
• W2110032523 startingPage "6080" @default.
• W2110032523 abstract "3-Iodoacetamido benzoyl ethyl ester (3-IAABE) is a new compound synthesized in our laboratory. The primary action of 3-IAABE is to inhibit microtubule assembly by interacting with -SH groups on tubulin. In contrast to other known microtubule disrupters, 3-IAABE caused a double blockade in the cell cycle at G(1)-S transition and in M phase. The blockade was determined by cell cycle analysis and chromosome distribution. Kinase activities of cyclin E and cyclin-dependent kinase 2 responsible for the G(1)-S transition were increased, as were the activities of mitotic cyclin B and cdc2. 3-IAABE treatment also increased p53 expression and dephosphorylated (or activated) retinoblastoma protein. Investigation of the signal transduction pathway showed that 3-IAABE induced bcl-2 phosphorylation, followed by activation of caspase-9, -3, and -6, but not caspase-8. DNA fragmentation factor and poly(ADP-ribose) polymerase, the downstream substrates of caspase-3 and -6, were cleaved after 3 h of exposure to 3-IAABE, followed by DNA fragmentation. Pretreatment of the cells with inhibitors of caspase-9, -3, or -6, respectively, inhibited the cleavage of DNA fragmentation factor and poly(ADP-ribose) polymerase and thus inhibited the onset of apoptosis. 3-IAABE showed antitumor activities in the panel of 60 National Cancer Institute human tumor cell lines with total growth inhibition in the range of 0.22-4.3 micro M for solid tumor lines and 0.025-0.22 micro M for leukemia/lymphoma cell lines. The 3-IAABU total growth inhibition of phytohemagglutinin-stimulated healthy human lymphocytes was 450-fold greater than that of leukemic cells. 3-IAABE significantly inhibited the growth of human hepatocarcinoma (BEL-7402) in nude mice by 72% in tumor volume, more strongly than did vincristine (43 percent inhibition). Besides being a novel lead for the design of new anticancer tubulin ligands, the activity of 3-IAABE in the cell cycle may also help us to understand the molecular pharmacology of microtubule-active drugs." @default.
• W2110032523 created "2016-06-24" @default.
• W2110032523 creator A5016728412 @default.
• W2110032523 creator A5033632697 @default.
• W2110032523 creator A5038805449 @default.
• W2110032523 creator A5049664169 @default.
• W2110032523 creator A5055370865 @default.
• W2110032523 creator A5058344556 @default.
• W2110032523 creator A5060696444 @default.
• W2110032523 creator A5063025231 @default.
• W2110032523 creator A5063782544 @default.
• W2110032523 creator A5064616037 @default.
• W2110032523 creator A5071748241 @default.
• W2110032523 creator A5072965952 @default.
• W2110032523 creator A5086902278 @default.
• W2110032523 date "2002-11-01" @default.
• W2110032523 modified "2023-10-18" @default.
• W2110032523 title "Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand." @default.
• W2110032523 cites W1481958162 @default.
• W2110032523 cites W1538781989 @default.
• W2110032523 cites W1547132539 @default.
• W2110032523 cites W1559603064 @default.
• W2110032523 cites W1572645371 @default.
• W2110032523 cites W1580311544 @default.
• W2110032523 cites W1585980551 @default.
• W2110032523 cites W1692919389 @default.
• W2110032523 cites W1775050147 @default.
• W2110032523 cites W1976384461 @default.
• W2110032523 cites W1980237452 @default.
• W2110032523 cites W1983347917 @default.
• W2110032523 cites W1993570389 @default.
• W2110032523 cites W1997005484 @default.
• W2110032523 cites W1999314985 @default.
• W2110032523 cites W2000692224 @default.
• W2110032523 cites W2001006416 @default.
• W2110032523 cites W203030802 @default.
• W2110032523 cites W2040503127 @default.
• W2110032523 cites W2045824232 @default.
• W2110032523 cites W2047578735 @default.
• W2110032523 cites W2051276257 @default.
• W2110032523 cites W2059187014 @default.
• W2110032523 cites W2064636836 @default.
• W2110032523 cites W2065252383 @default.
• W2110032523 cites W2070862399 @default.
• W2110032523 cites W2077587772 @default.
• W2110032523 cites W2082549567 @default.
• W2110032523 cites W2094334993 @default.
• W2110032523 cites W2101600612 @default.
• W2110032523 cites W2102981736 @default.
• W2110032523 cites W2113999599 @default.
• W2110032523 cites W2117500548 @default.
• W2110032523 cites W2118873545 @default.
• W2110032523 cites W2142423276 @default.
• W2110032523 cites W2146428402 @default.
• W2110032523 cites W2155208683 @default.
• W2110032523 cites W2159650080 @default.
• W2110032523 cites W2314037093 @default.
• W2110032523 cites W2334576637 @default.
• W2110032523 cites W2444031732 @default.
• W2110032523 cites W25117316 @default.
• W2110032523 cites W1924659121 @default.
• W2110032523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12414632" @default.
• W2110032523 hasPublicationYear "2002" @default.
• W2110032523 type Work @default.
• W2110032523 sameAs 2110032523 @default.
• W2110032523 citedByCount "9" @default.
• W2110032523 countsByYear W21100325232013 @default.
• W2110032523 countsByYear W21100325232014 @default.
• W2110032523 countsByYear W21100325232016 @default.
• W2110032523 countsByYear W21100325232017 @default.
• W2110032523 crossrefType "journal-article" @default.
• W2110032523 hasAuthorship W2110032523A5016728412 @default.
• W2110032523 hasAuthorship W2110032523A5033632697 @default.
• W2110032523 hasAuthorship W2110032523A5038805449 @default.
• W2110032523 hasAuthorship W2110032523A5049664169 @default.
• W2110032523 hasAuthorship W2110032523A5055370865 @default.
• W2110032523 hasAuthorship W2110032523A5058344556 @default.
• W2110032523 hasAuthorship W2110032523A5060696444 @default.
• W2110032523 hasAuthorship W2110032523A5063025231 @default.
• W2110032523 hasAuthorship W2110032523A5063782544 @default.
• W2110032523 hasAuthorship W2110032523A5064616037 @default.
• W2110032523 hasAuthorship W2110032523A5071748241 @default.
• W2110032523 hasAuthorship W2110032523A5072965952 @default.
• W2110032523 hasAuthorship W2110032523A5086902278 @default.
• W2110032523 hasConcept C105696609 @default.
• W2110032523 hasConcept C120504264 @default.
• W2110032523 hasConcept C153911025 @default.
• W2110032523 hasConcept C182979987 @default.
• W2110032523 hasConcept C185592680 @default.
• W2110032523 hasConcept C18903297 @default.
• W2110032523 hasConcept C190283241 @default.
• W2110032523 hasConcept C191015642 @default.
• W2110032523 hasConcept C2778437423 @default.
• W2110032523 hasConcept C29537977 @default.
• W2110032523 hasConcept C31573885 @default.
• W2110032523 hasConcept C43759708 @default.
• W2110032523 hasConcept C552990157 @default.
• W2110032523 hasConcept C55493867 @default.

• next